Zynerba Press Releases

28 Feb 22 Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

28 Feb 22 Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

15 Feb 22 Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

10 Feb 22 Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference

6 Jan 22 Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

4 Jan 22 Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

6 Dec 21 Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

22 Nov 21 Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

15 Nov 21 Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights

21 Oct 21 Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October